<DOC>
	<DOCNO>NCT02126358</DOCNO>
	<brief_summary>To evaluate efficacy safety fix-dose combination therapy Gemigliptin 50mg Rosuvastatin 20mg type 2 diabetes dyslipidemia</brief_summary>
	<brief_title>Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3 ( BALANCE )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Type 2 Diabetes Mellitus Dyslipidemia Adults least 19 year old Patients type 1 diabetes , diabetic ketoacidosis , diabetic coma precoma Patients gestational diabetes secondary diabetes Patients NYHA Class III , IV congestive heart failure arrhythmia require treatment Patients thyroid gland dysfunction deviate normal TSH range Patients pituitary insufficiency adrenal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>